Deciphera Pharmaceuticals, Inc. DCPH
At closeJun 10, 2024, 4:00 PM EDT
52-week range unavailable
- Market cap
- 2.21B
- Revenue (ttm)
- 174.91M
- Profit margin
- -108.86%
- Shares out
- 86.48M
- Forward P/E
- -15.23
- Volume
- 1.57M
- Open
- 25.56
- Previous close
- 25.59
- Day's range
- 25.56 – 25.61
- Beta
- 0.18
- Analysts
- Hold
- Price target
- 27.52 (+7.5%)
- Earnings date
- May 10, 2024
Key statistics
- Enterprise value
- 1.97B
- PEG ratio
- -0.62
- Price / sales
- 12.65
- Price / book
- 6.65
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 34.50%
- Free cash flow
- -80.09M
- Total cash
- 272.53M
- Total debt
- 25.02M
- Return on equity
- -50.37%
- Short % of float
- 6.33%
- 50-day average
- 21.67
- 200-day average
- 15.94
Analyst view
Consensus: hold
- Target (low)
- 25.60
- Target (mean)
- 27.52
- Target (high)
- 30.00
- Strong buy0
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
May 10, 2024
Expected May 10, 2024. Consensus EPS estimate -0.51.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 10, 2024 | Mar 1, 2024 | -0.55 | — | — | — |
| Feb 6, 2024 | Dec 1, 2023 | -0.58 | — | — | — |
| Oct 30, 2023 | Sep 1, 2023 | -0.60 | — | — | — |
| Aug 9, 2023 | Jun 1, 2023 | -0.62 | — | — | — |
| May 3, 2023 | Mar 1, 2023 | -0.60 | — | — | — |
| Feb 7, 2023 | Dec 1, 2022 | -0.57 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 9, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 9, 2023 | Stifel | up | Hold | Buy |
| Jun 4, 2023 | JMP Securities | reit | — | Market Outperform |
| May 3, 2023 | JMP Securities | reit | — | Market Outperform |
| Mar 14, 2023 | JMP Securities | reit | — | Market Outperform |
| Feb 7, 2023 | HC Wainwright & Co. | reit | — | Buy |
About Deciphera Pharmaceuticals, Inc.
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts. As of June 11, 2024, Deciphera Pharmaceuticals, Inc. operates as a subsidiary of Ono Pharmaceutical Co., Ltd.
- Sector
- Healthcare
- Industry
- Drug Manufacturers—Specialty & Generic
- Country
- United States
- Website
- deciphera.com
News
S&P 500 Edges Higher; ON Semiconductor Earnings Top Views 
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session - 12 Health Care Stocks Moving In Monday's Intraday Session
- Crude Oil Down Over 1%; Deciphera Pharmaceuticals Shares Spike Higher
Tesla, Deciphera Pharmaceuticals, Heartland Financial And Other Big Stocks Moving Higher On Monday 
12 Health Care Stocks Moving In Monday's Pre-Market Session 
Earnings Scheduled For February 6, 2024 - Stocks That Hit 52-Week Lows On Tuesday
Stocks That Hit 52-Week Lows On Thursday - Stocks That Hit 52-Week Lows On Thursday
Your note
Sign in to keep a note on DCPH — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BRIGHTSTARS ASSOCIATES, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Apr 21, 2024 | 23,107,800 |
| DHANAK DASHYANT | Officer | Stock Award(Grant) | Jun 10, 2024 | 0 |
| FLYNN DANIEL LEE | Officer | Sale | Jun 15, 2023 | 378,613 |
| FRIEDMAN FRANKLIN STUART | Director | Purchase | Jun 7, 2023 | 10,000 |
| HOERTER STEVEN L | Chief Executive Officer | Stock Award(Grant) | Jun 10, 2024 | 0 |
| KELLY THOMAS P. | Chief Financial Officer | Sale | Jun 15, 2023 | 57,140 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Deerfield Management Company, L.P. (Series C) | 8.51% | 6,707,026 | 94.43M | Jun 29, 2023 |
| Blackrock Inc. | 6.94% | 5,467,999 | 76.99M | Jun 29, 2023 |
| Redmile Group, LLC | 6.19% | 4,878,566 | 68.69M | Jun 29, 2023 |
| Armistice Capital, LLC | 5.79% | 4,560,000 | 64.20M | Jun 29, 2023 |
| Vanguard Group Inc | 5.57% | 4,392,270 | 61.84M | Jun 29, 2023 |
| Braidwell LP | 4.63% | 3,646,419 | 51.34M | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 2.47% | 1,947,744 | 27.35M | Aug 30, 2023 |
| Vanguard Total Stock Market Index Fund | 2.23% | 1,760,798 | 24.79M | Jun 29, 2023 |
| iShares Russell 2000 ETF | 1.52% | 1,194,319 | 16.77M | Aug 30, 2023 |
| Vanguard Extended Market Index Fund | 1.02% | 801,229 | 11.28M | Jun 29, 2023 |
| Vanguard Strategic Equity Fund | 0.95% | 747,816 | 10.53M | Jun 29, 2023 |
| College Retirement Equities Fund-Stock Account | 0.83% | 653,297 | 9.20M | Jun 29, 2023 |